Skip to search boxSkip to navigationSkip to main content

Design of immunogenic and effective multi-epitope DNA vaccines for melanoma

  • Hyun Il Cho
    ,
  • Esteban Celis(corresponding author)
*Corresponding author for this work
  • Moffitt Cancer Center
    ,
  • University of South Florida
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Plasmid DNA vaccination is an attractive way to elicit T cell responses against infectious agents and tumor cells. DNA constructs can be designed to contain multiple T cell epitopes to generate a diverse immune response to incorporate numerous antigens and to reduce limitations due to MHC restriction into a single entity. We have prepared cDNA plasmid constructs containing several mouse T cell epitopes connected by either furin-sensitive or furin-resistant linkers and studied the effects of a cationic cell-penetrating sequence from HIV-tat. Significant CD8 T cell responses were obtained with multi-epitope DNA vaccines followed by in vivo electroporation regardless of the type of linker used and whether the construct had the HIV-tat sequence. The magnitude of immune responses was very similar to all CD8 T cell epitopes contained within each vaccine construct, indicating the absence of immunodominance. Incorporating a T helper epitope into the constructs increased the T cell responses. Prophylactic and therapeutic antitumor responses against B16 melanoma were obtained using a construct containing epitopes from melanosomal proteins, indicating that this vaccination was successful in generating responses to self-antigens that potentially may be subjected to immune tolerance. These findings are useful for designing DNA vaccines for a multitude of diseases where T lymphocytes play a protective or therapeutic role.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 343-351 (9 pages)

Journal (Volume, Issue Number)

Cancer Immunology, Immunotherapy (Volume 61, Issue 3)

Publication milestones

  • Published - 03/2012

Publication status

Published - 03/2012

ISSN

0340-7004

Publication IDs

  • Scopus: 84860799184
  • PubMed: 21915800

Publication metrics

Metrics

SciVal
citations
26
Scopus
citations
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
0.50
Fractional count
1
Fractional count
1
SciVal
FWCI
0.75
SciVal
Author count
2
SciVal
Paper percentile
83

PlumX, opens in new tab

Captures
57
Social media
6
Citation count
30

Funding Details

Acknowledgments We dedicate this work to the memory of our friend and colleague Dr. Joseph Lustgarten, tumor immunologist who passed away on June 30, 2011. This work was supported by a grant from the MoYtt Comprehensive Melanoma Research Center. The authors declare no conXict of interest.